These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 8573079)

  • 1. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
    Aparicio C; Dahlbäck B
    Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
    Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
    Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
    Heeb MJ; Kojima Y; Greengard JS; Griffin JH
    Blood; 1995 Jun; 85(12):3405-11. PubMed ID: 7780127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V.
    Thorelli E; Kaufman RJ; Dahlbäck B
    Blood; 1999 Apr; 93(8):2552-8. PubMed ID: 10194434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated protein C resistance: molecular mechanisms.
    Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
    Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1995 Jul; 74(1):139-48. PubMed ID: 8578447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
    Dahlbäck B; Zöller B; Hillarp A
    Haemostasis; 1996 Oct; 26 Suppl 4():301-14. PubMed ID: 8979136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel factor V compound heterozygous mutation associated with thrombosis (Y1961C; FV-Kanazawa, together with 1982_1983del).
    Shimonishi N; Morishita E; Ogiwara K; Maruyama K; Yoshida J; Horie K; Nogami K
    J Thromb Haemost; 2024 Oct; 22(10):2810-2822. PubMed ID: 38950780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay.
    Kalafatis M; Haley PE; Lu D; Bertina RM; Long GL; Mann KG
    Blood; 1996 Jun; 87(11):4695-707. PubMed ID: 8639839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbohydrate moieties on the procofactor factor V, but not the derived cofactor factor Va, regulate its inactivation by activated protein C.
    Silveira JR; Kalafatis M; Tracy PB
    Biochemistry; 2002 Feb; 41(5):1672-80. PubMed ID: 11814362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor V and thrombotic disease: description of a janus-faced protein.
    Nicolaes GA; Dahlbäck B
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel APC-cleavage sites in FVa provide insights into mechanisms of action of APC and its cofactor protein S.
    Tran S; Dahlbäck B
    J Thromb Haemost; 2010 Jan; 8(1):129-36. PubMed ID: 19874463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.
    Cramer TJ; Griffin JH; Gale AJ
    Pathophysiol Haemost Thromb; 2010; 37(1):17-23. PubMed ID: 20501981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V.
    Thorelli E; Kaufman RJ; Dahlbäck B
    J Biol Chem; 1998 Jun; 273(26):16140-5. PubMed ID: 9632668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.
    Nogami K; Shinozawa K; Ogiwara K; Matsumoto T; Amano K; Fukutake K; Shima M
    Blood; 2014 Apr; 123(15):2420-8. PubMed ID: 24523236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of recombinant FV Hong Kong and FV Cambridge.
    Norstrøm E; Thorelli E; Dahlbäck B
    Blood; 2002 Jul; 100(2):524-30. PubMed ID: 12091344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.
    Egan JO; Kalafatis M; Mann KG
    Protein Sci; 1997 Sep; 6(9):2016-27. PubMed ID: 9300501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.